Scientists at the Icahn School of Medicine at Mount Sinai have made a key discovery about how human cells make RNA, a molecule that carries important instructions inside our bodies.
Mayo Clinic researchers have identified a potential new way to monitor the progression of high-grade gliomas, one of the most aggressive types of brain cancer.
The American College of Radiology released a statement in response to the recent paper, “Projected Lifetime Cancer Risks From Current Computed Tomography Imaging,” published in JAMA Internal Medicine.
Most patients who enroll in the Lung-MAP precision medicine trial in non-small cell lung cancer can now be matched to a targeted investigational treatment based on the results of their prior genomic testing, without needing to submit new tumor or blood samples.
Rates of colorectal cancer diagnoses dropped during and shortly after Hurricanes Irma and Maria and the COVID-19 pandemic in Puerto Rico, according to a recent analysis led by investigators at the University of Puerto Rico.
Physicians at Tampa General Hospital and USF Health Morsani College of Medicine conducted a multicenter, retrospective cohort study and found that a highly specialized treatment—heated intraperitoneal chemotherapy delivered directly into the abdominal cavity, is associated with longer survival for women with metastatic epithelial ovarian cancer.
Faron Pharmaceuticals Ltd. on April 14 announced positive topline results of the BEXMAB trial, which shows a high overall response rate among both frontline as well as relapsed/refractory high-risk myelodysplastic syndromes patients treated with a combination of bexmarilimab and azacitidine.
Researchers at City of Hope have identified a new molecular target for treating pancreatic cancer, reports a Gastroenterologystudy published on April 8.
Most cancer genome studies have focused on mutations in the tumor itself and how such gene variants allow a tumor to grow unchecked. A study led by researchers at Washington University School of Medicine in St. Louis takes a deep dive into inherited cancer mutations measured in a healthy blood sample and reports how those mutations might take a toll on the body’s cells starting at birth, perhaps predisposing a person to develop cancers at various stages of life.
Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a recent study led by researchers at NYU Langone Health and its Perlmutter Cancer Center shows.
